Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.610
NA - Nord America 15.305
EU - Europa 10.764
SA - Sud America 2.318
AF - Africa 237
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 15
Totale 44.269
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.903
SG - Singapore 5.655
HK - Hong Kong 3.666
RU - Federazione Russa 2.984
VN - Vietnam 2.833
CN - Cina 2.212
BR - Brasile 1.866
IT - Italia 1.864
IE - Irlanda 1.761
DE - Germania 1.385
SE - Svezia 1.245
GB - Regno Unito 365
IN - India 365
CA - Canada 281
UA - Ucraina 234
AR - Argentina 185
ID - Indonesia 162
FI - Finlandia 151
KR - Corea 135
NL - Olanda 132
AT - Austria 124
FR - Francia 117
BD - Bangladesh 105
ZA - Sudafrica 97
MX - Messico 86
PL - Polonia 84
ES - Italia 74
EC - Ecuador 73
IQ - Iraq 72
TR - Turchia 66
JP - Giappone 65
DK - Danimarca 53
CO - Colombia 51
VE - Venezuela 42
BE - Belgio 39
PK - Pakistan 38
PY - Paraguay 33
SA - Arabia Saudita 30
MY - Malesia 29
CL - Cile 28
EG - Egitto 27
CZ - Repubblica Ceca 26
MA - Marocco 26
KE - Kenya 21
UZ - Uzbekistan 21
TN - Tunisia 20
JO - Giordania 18
PT - Portogallo 17
RO - Romania 16
LT - Lituania 15
PE - Perù 15
TW - Taiwan 15
DZ - Algeria 14
IR - Iran 14
UY - Uruguay 13
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
EU - Europa 12
AL - Albania 11
BO - Bolivia 11
IL - Israele 11
OM - Oman 10
AU - Australia 9
BG - Bulgaria 9
PH - Filippine 9
DO - Repubblica Dominicana 8
JM - Giamaica 8
NO - Norvegia 8
NP - Nepal 8
AZ - Azerbaigian 7
BH - Bahrain 6
ET - Etiopia 6
KG - Kirghizistan 6
PA - Panama 6
SN - Senegal 6
AO - Angola 5
BY - Bielorussia 5
GR - Grecia 5
KZ - Kazakistan 5
LB - Libano 5
RS - Serbia 5
TH - Thailandia 5
XK - ???statistics.table.value.countryCode.XK??? 5
EE - Estonia 4
HN - Honduras 4
KW - Kuwait 4
LY - Libia 4
MD - Moldavia 4
MM - Myanmar 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
CI - Costa d'Avorio 3
CR - Costa Rica 3
GA - Gabon 3
HU - Ungheria 3
LK - Sri Lanka 3
QA - Qatar 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
Totale 44.241
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.655
Singapore 3.052
Dublin 1.711
Ashburn 1.463
Ann Arbor 1.271
Frankfurt am Main 976
Ho Chi Minh City 922
Princeton 886
New York 835
Hanoi 750
Fairfield 672
Chandler 662
Santa Clara 610
Dallas 536
Milan 468
Woodbridge 464
Houston 456
Los Angeles 391
Moscow 360
The Dalles 330
Lawrence 327
Beijing 322
Altamura 321
Wilmington 316
Hefei 285
Seattle 252
Cambridge 249
Buffalo 222
Chicago 180
Shanghai 179
São Paulo 171
Jacksonville 167
San Diego 160
Pune 157
Dearborn 143
Rome 134
Jakarta 128
Seoul 121
Toronto 118
London 98
Andover 89
Haiphong 88
Da Nang 84
Salt Lake City 84
Nuremberg 81
Rio de Janeiro 73
Guangzhou 69
Quận Bình Thạnh 65
Vienna 64
Helsinki 63
Munich 63
Nanjing 62
Warsaw 62
Tokyo 58
Washington 58
Brooklyn 53
Hải Dương 53
Thái Nguyên 53
Ha Long 49
Hangzhou 49
Biên Hòa 48
Johannesburg 47
San Jose 45
Boston 44
Montreal 43
Stockholm 43
Atlanta 41
Ninh Bình 40
Phoenix 40
Vũng Tàu 40
Boardman 38
Chennai 38
Council Bluffs 38
Fremont 38
Brasília 36
Denver 35
Tampa 35
Columbus 34
Lappeenranta 34
Orem 34
Belo Horizonte 32
Bergamo 32
Elk Grove Village 32
Quận Phú Nhuận 30
Curitiba 29
Mexico City 29
Poplar 29
Shenyang 29
Changsha 28
Lachine 28
Quito 28
San Francisco 28
Ottawa 27
Quận Một 27
Tianjin 27
Brussels 26
Bắc Ninh 25
Can Tho 25
Guayaquil 25
Manchester 25
Totale 27.192
Salva come PNG Salva come JPEG
Nome #
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma 1.234
Vaccinations in Paediatric Solid Organ Transplant Candidates and Recipients 438
Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group 433
Estimation of lifetime costs for patients receiving a transplant: the case of liver transplantation related to hepatitis B in Italy 431
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 399
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 336
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 302
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 289
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 278
Health related quality of life in chronic liver diseases 277
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 271
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 265
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 261
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 261
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 256
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 255
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 253
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 251
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 251
High rates of 30-day mortality in patients with cirrhosis and COVID-19 247
The impact of liver disease on the health-related quality of life 246
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 245
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 236
Health Related Quality of Life in the Major Liver Conditions 236
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 235
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 235
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 235
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 227
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 227
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 223
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 219
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 219
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 215
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 214
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 212
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 210
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 209
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 204
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 203
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 201
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 199
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 198
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 196
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 193
Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients 191
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 191
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 191
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 189
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 188
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 186
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 179
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 179
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 179
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 179
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients 177
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 174
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 174
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 173
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 172
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 172
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 172
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 166
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group (Hepatology International, (2024), 18, 5, (1416-1430), 10.1007/s12072-024-10703-4) 165
Percutaneous management of chronic total occlusion of the portal vein: a retrospective analysis of technical aspects and outcomes 165
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 165
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 164
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 163
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 163
Bergamo and Covid-19: How the Dark Can Turn to Light 162
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 161
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 161
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 160
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 159
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 156
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 153
Antibiotic Stewardship Based on Colonization with Multi-Drug-Resistant Bacteria in Liver Transplantation: A Narrative Review 152
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 150
The Role of Imaging in Portal Vein Thrombosis: From the Diagnosis to the Interventional Radiological Management 149
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 149
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 147
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue 146
Current Endovascular Management of Arterial Complications After Pediatric Liver Transplantation in a Tertiary Center 143
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool 141
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 141
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 140
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study 139
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 139
Extended criteria liver donation after circulatory death with prolonged warm ischemia: a pilot experience of normothermic regional perfusion and no subsequent ex-situ machine perfusion 139
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 138
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 137
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using “on demand” Approach: A Single Center Experience 137
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness 136
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation 136
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 136
Citolisi e colestasi post-oltx per cirrosi HCV: l’enigma della diagnosi differenziale 136
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 135
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 133
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial 132
Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19 131
Non-anatomical revascularization of the portal vein in children with non-cirrhotic extrahepatic portal vein obstruction 127
Totale 21.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 215.865
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 215.865
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021758 0 0 0 0 0 0 134 162 120 118 79 145
2021/20223.656 81 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20245.053 74 128 152 226 754 1.452 973 162 461 73 64 534
2024/202514.328 822 1.742 601 606 1.226 389 614 462 2.010 1.826 966 3.064
2025/202613.314 2.866 1.925 1.987 2.256 2.707 1.476 97 0 0 0 0 0
Totale 45.917